GART

Across TCGA pan-cancer cohorts, GART mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated GART data layer compared with 24 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher GART mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated GART expression acts as an unfavorable survival marker, although some lineages such as LUAD and LSCC show a favorable association.

LUAD, CCRCC, and LSCC are the cancer types where GART mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Median	II,III,IV	0.938	0.733	.002	16	view →
CCRCC	OS	Median	IV	0.123	0.785	.009	9	view →
LSCC	DFS	Tertile	All	0.975	0.908	.013	7	view →
HNSC	OS	Median	III,IV	1.000	0.449	.023	6	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

GART–LUAD (DFS)

Open the LUAD breakdown →